Credit Suisse’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Credit Suisse’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-49,704	Closed	-$129K	–	3186
2023 Q2	$129K	Buy	49,704 +12,122	+32%	+$43.2K	﹤0.01%	3125
2023 Q1	$153K	Buy	37,582 +2,988	+9%	+$13.8K	﹤0.01%	3164
2022 Q4	$174K	Buy	34,594 +6,885	+25%	+$43.2K	﹤0.01%	3221
2022 Q3	$362K	Buy	27,709 +194	+0.7%	+$2.94K	﹤0.01%	2987
2022 Q2	$352K	Buy	27,515 +2,961	+12%	+$41K	﹤0.01%	3067
2022 Q1	$374K	Sell	24,554 -400	-2%	-$6.24K	﹤0.01%	3129
2021 Q4	$443K	Buy	24,954 +5,845	+31%	+$112K	﹤0.01%	3904
2021 Q3	$402K	Buy	19,109 +4,296	+29%	+$94.6K	﹤0.01%	3948
2021 Q2	$292K	Buy	+14,813	New	+$347K	﹤0.01%	4125

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's NGM Position: Q3 2023 in Review

Credit Suisse sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 49,704 shares — an estimated $129K sold.

Credit Suisse first reported a position in NGM in Q2 2021 and held it in 9 quarters. The position peaked at $443K in Q4 2021. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

Credit Suisse reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Credit Suisse sold 49,704 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $129K.
Credit Suisse first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
Credit Suisse's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $443K in Q4 2021.
94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.